Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense

In addition to the United States, Biogen has asked regulators in Australia, Brazil, Canada, the European Union, Japan and Switzerland to ...


In addition to the United States, Biogen has asked regulators in Australia, Brazil, Canada, the European Union, Japan and Switzerland to review the drug.

The U.S. approval is a crucial victory for a company that has been counting on Aduhelm to make up for stalled or declining revenue from its other products. Competitors last year introduced generic versions of Biogen’s multiple sclerosis drug, Tecfidera, causing the company to miss out on hundreds of millions of dollars in revenue from what had been its top-selling product.

The approval “completely transforms” Biogen, said Brian Skorney, an analyst at Robert W. Baird & Company, who is projecting that the drug will generate $7.5 billion in revenue in 2025. “This changes it from a declining revenue company to a growth company,” he said, and, in so doing, “opens up a bit of Pandora’s box” in terms of pricing and reimbursement.

While only patients with mild cognitive decline were enrolled in the clinical trials, the F.D.A. approved the drug for anyone with Alzheimer’s, a much broader group of patients than many experts were expecting.

Just how lucrative the drug will be for Biogen will depend on how many patients it can reach — and in what circumstances, and for how long, insurers are willing to pay for it.

Dr. Steve Miller, the chief clinical officer at the insurer Cigna, said on Monday that he expected his company and most of its peers would pay for the drug only for patients with mild cognitive symptoms and higher-than-normal levels of the protein amyloid in their brains.

“There’s just no data that more advanced patients will benefit,” he said.

Dr. Miller said he was disappointed that the F.D.A. had made so many patients eligible. “You’re leaving the tough decision-making about who should be covered to the individual payers,” he said.

Source Link

COMMENTS

Name

Africa,821,Americas,4125,Art & Culture,14982,Arts,6509,Arts & Design,1676,Asia,3288,Automobile,464,Baseball,637,Basketball,530,Books,3903,Business,5356,Celebrity,2633,Cricket,648,Crime,158,Cryptocurrency,1586,Dance,672,Defense,836,Diplomatic Relations,2496,Economy,1151,Editorial,260,Education,1256,Elections,308,Energy & Environment,3076,Entertainment,22735,Environment,3627,Europe,4237,Faith & Religion,235,Family & Life,817,Fashion & Style,3276,Finance,20024,Food & Drink,3759,Football,1111,Games,97,Gossip,10289,Health & Fitness,4104,Health Care,937,Hockey,228,Home & Garden,920,Humour,994,Latin America,49,Lifestyle,17133,Media,527,Middle East,1538,Movies,1736,Music,2662,Opinion,3093,Other,11965,Other Sports,5058,Political News,11324,Political Protests,2324,Politics,17748,Real Estate,1872,Relationship,106,Retail,3116,Science,2643,Science & Tech,10067,Soccer,244,Space & Cosmos,349,Sports,12283,Technology,3448,Tennis,582,Theater,1692,Transportation,313,Travel,2580,TV,3696,US,282,US Sports,1481,Video News,3531,War & Conflict,1069,Weird News,998,World,16547,
ltr
item
Newsrust - US Top News: Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
https://static01.nyt.com/images/2021/06/08/business/08aducanumab-1/08aducanumab-1-facebookJumbo.jpg
Newsrust - US Top News
https://www.newsrust.com/2021/06/alzheimers-drug-is-bonanza-for-biogen.html
https://www.newsrust.com/
https://www.newsrust.com/
https://www.newsrust.com/2021/06/alzheimers-drug-is-bonanza-for-biogen.html
true
732247599994189300
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy Table of Content